Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Musculoskeletal and connective tissue neoplasms

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44412   clinical trials with a EudraCT protocol, of which   7421   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5 result(s) found for: Musculoskeletal and connective tissue neoplasms. Displaying page 1 of 1.
    EudraCT Number: 2020-005626-29 Sponsor Protocol Number: IRFMN-SARCO-7953 Start Date*: 2021-05-05
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: A phase II study on trabectedin in combination with PPARg agonist pioglitazone in patients with round cell myxoid liposarcomas or dedifferentiated G1 and G2 liposarcomas with stable disease after a...
    Medical condition: Patients with myxoid/round cell liposarcoma treated with at least 4 cycle of T alone with a stable disease at the last tumor evaluation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10028395 Musculoskeletal and connective tissue disorders SOC
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024628 Liposarcomas malignant HLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073139 Round cell liposarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073137 Myxoid liposarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-005244-42 Sponsor Protocol Number: 20159990 Start Date*: 2018-06-04
    Sponsor Name:Leiden University Medical Center
    Full Title: An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects with Giant Cell Rich Tumors of Bone.
    Medical condition: Aneurysmal bone cysts, giant cell granuloma, other giant cell rich lesions (primary bone, non-malignant)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10018252 Giant cell granuloma peripheral LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004430 Benign osteoblastoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008686 Chondroblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008733 Chondromyxoid fibroma LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10002362 Aneurysmal bone cyst PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-012076-26 Sponsor Protocol Number: 20080560 Start Date*: 2009-10-01
    Sponsor Name:Amgen Inc
    Full Title: A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects with Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss due to Androgen-Deprivati...
    Medical condition: Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy (ADT) for Non-metastatic Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10065687 Bone loss LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) CZ (Completed) PL (Completed) LV (Completed) GR (Completed) SK (Completed) BG (Completed) HU (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2011-005790-23 Sponsor Protocol Number: N/A Start Date*: 2012-07-17
    Sponsor Name:Birmingham Children's Hospital NHS Foundation Trust
    Full Title: Comparison of adrenal recovery following short and long-term glucocorticoid therapy.
    Medical condition: Adrenal recovery following long and short term steroid treatment.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10066550 Chronic arthritis LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000842 Acute lymphatic leukaemia LLT
    14.1 10019805 - Hepatobiliary disorders 10008953 Chronic liver disease LLT
    14.1 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-006154-17 Sponsor Protocol Number: 20080537 Start Date*: 2009-07-20
    Sponsor Name:Amgen Inc
    Full Title: An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastati...
    Medical condition: medical condition should be "Bone Loss in patients undergoing androgen-deprivation therapy (ADT) for non-metastatic prostate cancer"
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065687 Bone loss LLT
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed) CZ (Completed) HU (Completed) PL (Completed) FI (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Oct 16 08:36:47 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA